; (B) registries and clinical trials that include pregnant and lactating women; (2) encourage and facilitate participation by pregnant and lactating women in clinical research; (3) improve the general understanding of the critical role registries and other postmarket surveillance activities have in collecting data related to the use of medications by pregnant and lactating women; (4) improve the understanding of available clinical trials and registries that enroll pregnant and lactating women; (5) encourage pregnant and lactating women to seek additional information about such opportunities to participate in clinical research; (6) encourage health care providers to make information on clinical research available to pregnant and lactating women; and (7) facilitate access to and enrollment in such research by pregnant and lactating women. (b) Consultation In carrying out this section, the Secretary shall consult with— (1) nonprofit organizations with expertise related to the health of women and children, including those representing populations with high rates of maternal mortality and morbidity; (2) representatives from relevant medical societies with subject matter expertise on pregnant women, lactating women, or children; (3) relevant industry representatives; and (4) other representatives, as appropriate. (c) Planning In establishing the campaign under subsection (a), the Secretary, acting through the Director of the National Institutes of Health, in consultation with the heads of other relevant Federal agencies, shall— (1) conduct a needs assessment to— (A) evaluate existing resources; and (B) identify barriers to awareness and opportunities to fill gaps and address barriers; (2) identify target audiences for the campaign; (3) identify best practices to reach each such target audience; (4) test appropriate messaging strategies, including risk communication messaging, for each target audience